Hehlmann, R. (2019). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American journal of hematology, 94(1), . https://doi.org/10.1002/ajh.25306
Chicago-Zitierstil (17. Ausg.)Hehlmann, Rüdiger. "Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY." American Journal of Hematology 94, no. 1 (2019). https://doi.org/10.1002/ajh.25306.
MLA-Zitierstil (9. Ausg.)Hehlmann, Rüdiger. "Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY." American Journal of Hematology, vol. 94, no. 1, 2019, https://doi.org/10.1002/ajh.25306.